Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression.
Algorithm
EDSS
ICD-9 mapping
KFSS
MS disability
Real-world data
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
29
01
2021
accepted:
13
07
2021
pubmed:
2
8
2021
medline:
16
9
2021
entrez:
1
8
2021
Statut:
ppublish
Résumé
This article describes the development of a unique mapping of the Kurtzke Functional Systems Scores (KFSS) from International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes among multiple sclerosis (MS) patients within a US Integrated Delivery Network (IDN). Valid identification of increasing disability may allow deeper insight into MS progression and possible treatments. This cohort study identified MS patients in the IDN, Intermountain Healthcare. Experienced clinicians and informaticists mapped electronic health record ICD-9-CM codes to KFSS components generating a modified Kurtzke Expanded Disability Status Scale (EDSS). Modified EDSS scores were used to assess disability progression by calculating means, medians, ranges, and changes in KFSS and modified EDSS scores. Overall, 608/2960 (20.5%) patients were identified as having MS progression and presented a wide range of scores on the EDSS 10-point scale. The median (range) first and second EDSS scores were 0 (0-6) and 5 (1-8), respectively. The median (range) change from first to second score was 5 (1-7.5). The median first KFSS score for all systems was 0, and the mean differed among components. The highest mean first KFSS score (1.06) was measured for sensory function and lowest (0.12) for cerebellar functions. Of the 544 patients with their first EDSS scores in the ≤ 2.5 group, 75.2% and 15.1% had their second EDSS scores in group 3-5.5 and ≥ 6, respectively. Of the 62 patients with their first EDSS score in the 3-5.5 group, 58.1% had their second EDSS scores in group ≥ 6. This innovative mapping technique is a promising method for future comparative effectiveness and safety research of Disease-Modifying Therapy in Real-World Data repositories. Future research to validate and expand on this method in another healthcare database is encouraged.
Identifiants
pubmed: 34333756
doi: 10.1007/s12325-021-01858-9
pii: 10.1007/s12325-021-01858-9
pmc: PMC8408077
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4786-4797Informations de copyright
© 2021. The Author(s).
Références
Mult Scler. 1999 Oct;5(5):349-54
pubmed: 10516779
Neurology. 1996 Apr;46(4):907-11
pubmed: 8780061
Acta Neuropathol. 2012 May;123(5):627-38
pubmed: 22327362
J Neurol Sci. 1996 Jan;135(1):1-9
pubmed: 8926489
BMC Neurol. 2014 Mar 25;14:58
pubmed: 24666846
Value Health. 2019 Jan;22(1):77-84
pubmed: 30661637
Arch Neurol. 1999 Sep;56(9):1138-42
pubmed: 10488816
Brain. 1980 Jun;103(2):281-300
pubmed: 7397479
J Neurol. 2012 Sep;259(9):1814-23
pubmed: 22289966
Mult Scler. 2008 Aug;14(7):999-1002
pubmed: 18505776
J Neurol. 2018 Dec;265(12):2980-2992
pubmed: 30327931
Mult Scler. 1995 Apr;1(1):37-47
pubmed: 9345468
World J Clin Cases. 2015 Jul 16;3(7):545-55
pubmed: 26244148
Mult Scler. 2005 Feb;11(1):81-4
pubmed: 15732271
J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):439-42
pubmed: 12640058
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Brain. 1989 Feb;112 ( Pt 1):133-46
pubmed: 2917275
CNS Drugs. 2017 Mar;31(3):217-236
pubmed: 28185158